Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | February 18, 2020 | February 19, 2020 |
| Immunovant, Inc.IMVT · Entity 3632 | Director · Chief Executive Officer | October 01, 2026 | October 05, 2026 |
| Roivant Sciences Ltd.ROIV · Entity 3185 | President & Immunovant CEO | September 30, 2026 | October 02, 2026 |
| Sio Gene Therapies Inc.AXGT · Entity 130622 | Director | February 17, 2020 | February 19, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date February 18, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Immunovant, Inc.
Report date October 01, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 257,075 |
Ending reported balance
After 2026-10-02 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 92,187 · Balance 346,467 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 2 · 2026-10-01 · Disposition to issuer · Disposed 85,886 · Balance 260,581 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Row 3 · 2026-10-02 · Sale · Disposed 3,506 · Balance 257,075 F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. |
| Capped Value Appreciation RightsSEC Table II · derivative / convertible security · Conversion / exercise price $14.46 · Expires 2030-04-01 | Direct | 921,875 |
Reported balance
After 2026-10-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Disposed 92,187 · Balance 921,875 F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date.
F2: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026.
F3: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
F4: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share.
Roivant Sciences Ltd.
Report date September 30, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 1,599,154 |
Ending reported balance
After 2026-09-30 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-30 · Exercise / conversion · Acquired 200,000 · Balance 1,799,154 Row 2 · 2026-09-30 · Sale · Disposed 200,000 · Balance 1,599,154 F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.85 · Expires 2032-04-19 | Direct | 3,644,834 |
Reported balance
After 2026-09-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-30 · Exercise / conversion · Disposed 200,000 · Balance 3,644,834 F2: Reflects an award of stock options to purchase Common Shares that is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025.
F2: Reflects an award of stock options to purchase Common Shares that is fully vested.
Sio Gene Therapies Inc.
Report date February 17, 2020 · Filed February 19, 2020
This filing explicitly reported no securities owned.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 23:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,506 | $34.11 | $119,589.66 |
DisclosureSEC source: 0001764013-26-000110 · wk-form4_1791243741.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,075 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 23:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 92,187 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001764013-26-000110 · wk-form4_1791243741.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 921,875 Underlying: Common Stock · 92,187 shares Expires 2030-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.exercise_price: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F2 · derivative.exercise_date: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F4 · derivative.exercise_date: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. F1 · derivative.underlying_shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.underlying_shares: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 23:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerCommon Stock | 85,886 | $33.65 | $2,890,063.90 |
DisclosureSEC source: 0001764013-26-000110 · wk-form4_1791243741.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,581 F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Read SEC document |
| October 01, 2026 Filed Oct 5, 2026 23:42 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 92,187 | $14.46 | $1,333,024.02 |
DisclosureSEC source: 0001764013-26-000110 · wk-form4_1791243741.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 346,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On October 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,187 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on October 1, 2026. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 21:37 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,644,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 21:37 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $36.62 | $7,324,000.00 |
DisclosureSEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,599,154 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.49 to $36.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Read SEC document |
| September 30, 2026 Filed Oct 2, 2026 21:37 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000108 · wk-form4_1790977058.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,799,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 28, 2026 Filed Sep 2, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-035375 · form4.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,844,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| August 28, 2026 Filed Sep 2, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 33,818 | $36.44 | $1,232,327.92 |
DisclosureSEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,599,154 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.17 to $36.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Read SEC document |
| August 28, 2026 Filed Sep 2, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 166,182 | $35.63 | $5,921,064.66 |
DisclosureSEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,632,972 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.17 to $36.16, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. These sales were effected by the reporting person pursuant to a Rule 10b5-1 trading plan adopted on March 28, 2025. Read SEC document |
| August 28, 2026 Filed Sep 2, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001140361-26-035375 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,799,154 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2026 Filed Aug 25, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 13,909 | $36.84 | $512,407.56 |
DisclosureSEC source: 0001140361-26-034238 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,599,154 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| July 27, 2026 Filed Jul 30, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-030107 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,044,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| July 27, 2026 Filed Jul 30, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $34.95 | $6,990,000.00 |
DisclosureSEC source: 0001140361-26-030107 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,613,063 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.62 to $35.56, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| July 27, 2026 Filed Jul 30, 2026 01:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001140361-26-030107 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,813,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 21:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 3,092 | $38.48 | $118,980.16 |
DisclosureSEC source: 0001764013-26-000077 · wk-form4_1783371682.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 254,280 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 92,188 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001764013-26-000077 · wk-form4_1783371682.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,014,062 Underlying: Common Stock · 92,188 shares Expires 2030-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.exercise_price: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F2 · derivative.exercise_date: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F4 · derivative.exercise_date: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. F1 · derivative.underlying_shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.underlying_shares: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerCommon Stock | 86,629 | $38.14 | $3,304,030.06 |
DisclosureSEC source: 0001764013-26-000077 · wk-form4_1783371682.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 257,372 F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 21:01 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 92,188 | $14.46 | $1,333,038.48 |
DisclosureSEC source: 0001764013-26-000077 · wk-form4_1783371682.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 344,001 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On July 1, 2026, the Service Requirement (as defined in Footnote 4), Performance Requirement (as defined in Footnote 4), Knock-In Requirement (as defined in Footnote 4), and hurdle price applicable to 92,188 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on July 1, 2026. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 22:13 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,244,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 22:13 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 46,234 | $33.51 | $1,549,301.34 |
DisclosureSEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,613,063 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.23 to $33.98, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 22:13 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 153,766 | $33.05 | $5,081,966.30 |
DisclosureSEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,659,297 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.23 to $33.22, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| June 24, 2026 Filed Jun 26, 2026 22:13 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000071 · wk-form4_1782512028.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,813,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:25 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · derivative · entry 4 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,444,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:25 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $30.27 | $6,054,000.00 |
DisclosureSEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,613,063 F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| May 22, 2026 Filed May 22, 2026 22:25 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,813,063 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2026 Filed May 22, 2026 22:25 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 34,483 | $32.41 | $1,117,594.03 |
DisclosureSEC source: 0001635088-26-000065 · wk-form4_1779488744.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,613,063 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,644,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Reflects an award of stock options to purchase Common Shares that is fully vested. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $29.59 | $5,918,000.00 |
DisclosureSEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647,546 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.33 to $29.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| April 20, 2026 Filed Apr 22, 2026 22:27 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000044 · wk-form4_1776896865.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,847,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:13 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantStock Option (right to buy) · Derivative | 336,043 | $0.00 Strike: $24.61 | $0.00 |
DisclosureSEC source: 0001764013-26-000034 · wk-form4_1775765620.xml · derivative · entry 2 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,043 Underlying: Common Stock · 336,043 shares Expires 2036-04-07 F2 · derivative.exercise_date: These options were granted pursuant to the Plan. The shares underlying the options will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in thirty-six (36) successive substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 20:13 UTC | Immunovant, Inc. IMVT · Entity 3632 | GrantCommon Stock | 232,252 | $0.00 | $0.00 |
DisclosureSEC source: 0001764013-26-000034 · wk-form4_1775765620.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 251,813 F1 · shares: These restricted stock units ("RSUs") were granted pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan"). Each RSU represents a contingent right to receive one share of common stock upon the vesting of the unit. The RSUs will vest as to 25% of the total shares on April 1, 2027 and the balance will vest in twelve (12) successive substantially equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer as of such date. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 1,409 | $24.60 | $34,661.40 |
DisclosureSEC source: 0001764013-26-000024 · wk-form4_1775248378.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,561 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.51 - $24.70 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | SaleCommon Stock | 12,820 | $24.04 | $308,192.80 |
DisclosureSEC source: 0001764013-26-000024 · wk-form4_1775248378.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,970 F3 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these CVARs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.50 - $24.49 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCapped Value Appreciation Rights · Derivative | 368,750 | $0.00 Strike: $14.46 | $0.00 |
DisclosureSEC source: 0001764013-26-000024 · wk-form4_1775248378.xml · derivative · entry 5 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,106,250 Underlying: Common Stock · 368,750 shares Expires 2030-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.exercise_price: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F2 · derivative.exercise_date: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F6 · derivative.exercise_date: These CVARs vest on the first date that each of (i) the Service Requirement, (ii) the Performance Requirement, and (iii) the Knock-in Requirement have been satisfied. The "Service Requirement" is satisfied as follows: (i) 25% of the CVARs vested on April 1, 2026; and (ii) the remaining 75% vests in twelve (12) equal quarterly installments thereafter, subject to the Reporting Person's continuous service to the Issuer or an affiliate on each such vesting date. The "Performance Requirement" is tied to the achievement of a specified clinical development activity at the Issuer, which requirement was met as of March 31, 2026. The "Knock-in Requirement" requires that the price of the Issuer's common stock at each applicable vesting date must be equal to or greater than $16.76 per share. F1 · derivative.underlying_shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · derivative.underlying_shares: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | Disposition to issuerCommon Stock | 334,960 | $25.10 | $8,407,496.00 |
DisclosureSEC source: 0001764013-26-000024 · wk-form4_1775248378.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,790 F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:33 UTC | Immunovant, Inc. IMVT · Entity 3632 | Exercise / conversionCommon Stock | 368,750 | $14.46 | $5,332,125.00 |
DisclosureSEC source: 0001764013-26-000024 · wk-form4_1775248378.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · kind: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · shares: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · shares: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. F1 · price: On July 28, 2025, the Reporting Person was granted capped value appreciation rights ("CVARs"), as previously reported in a Form 4 filed on July 30, 2025, that entitle the Reporting Person to receive a payment equal to the product of (i) the number of vested CVARs multiplied by (ii) the excess (if any) of (A) the fair market value of the Issuer's common stock (capped at $16.76 per share) as of the relevant date of determination over (B) the applicable hurdle price of $14.46 (the "CVAR Amount"). The CVARs will then settle into a number of shares of common stock of the Issuer determined by dividing (i) the CVAR Amount by (ii) the fair market value of the Issuer's common stock as of such date. F2 · price: On April 1, 2026, the Service Requirement (as defined in Footnote 6), Performance Requirement (as defined in Footnote 6), Knock-In Requirement (as defined in Footnote 6), and hurdle price applicable to 368,750 vested CVARs were satisfied and, accordingly, the CVARs were settled into shares of the Issuer's common stock, determined by dividing (i) the CVAR Amount by (ii) the closing price of a share of the Issuer's common stock on April 1, 2026. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:36 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,844,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:36 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $28.24 | $5,648,000.00 |
DisclosureSEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,647,546 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.04 to $28.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| March 17, 2026 Filed Mar 19, 2026 22:36 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000026 · wk-form4_1773959801.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,847,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 20, 2026 Filed Feb 24, 2026 23:43 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Tax withholdingCommon Shares | 7,051 | $27.15 | $191,434.65 |
DisclosureSEC source: 0001635088-26-000022 · wk-form4_1771976596.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,647,546 F1 · shares: Represents the "net settlement" by the Issuer of RSUs previously granted to the reporting person in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of such RSUs. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001635088-26-000017 · wk-form4_1771455431.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,044,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the applicable vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $26.49 | $5,298,000.00 |
DisclosureSEC source: 0001635088-26-000017 · wk-form4_1771455431.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,654,597 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.35 to $26.69, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 22:57 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001635088-26-000017 · wk-form4_1771455431.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,854,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-26-001239 · form4.xml · derivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,244,834 Underlying: Common Stock · 200,000 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 200,000 | $21.92 | $4,384,000.00 |
DisclosureSEC source: 0001140361-26-001239 · form4.xml · nonDerivative · entry 2 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,654,597 F1 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.59 to $22.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. Read SEC document |
| January 12, 2026 Filed Jan 15, 2026 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 200,000 | $3.85 | $770,000.00 |
DisclosureSEC source: 0001140361-26-001239 · form4.xml · nonDerivative · entry 1 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,854,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionStock Option (Right to Buy) · Derivative | 117,848 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001140361-25-046786 · form4.xml · derivative · entry 6 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,444,834 Underlying: Common Stock · 117,848 shares Expires 2032-04-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Award of stock options to purchase Common Shares with a vesting commencement date of April 20, 2022. These options vest and become exercisable (i) 25% on the first anniversary of the vesting commencement date and (ii) in 36 equal monthly installments thereafter, subject generally to the reporting person's continuous service through each vesting date (unless otherwise provided in the applicable award documentation). Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | SaleCommon Shares | 75,000 | $22.53 | $1,689,750.00 |
DisclosureSEC source: 0001140361-25-046786 · form4.xml · nonDerivative · entry 4 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,654,597 F1 · shares: Represents an exercise and hold transaction, with a sale of Common Shares only to cover applicable withholding taxes and the exercise price of the stock options exercised. F2 · price: The price reported in column 4 is a weighted average price. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of Common Shares sold at each separate price within the range. F4 · price: These Common Shares were sold in multiple transactions at prices ranging from $22.50 to $22.63, inclusive. Read SEC document |
| December 24, 2025 Filed Dec 30, 2025 02:00 UTC | Roivant Sciences Ltd. ROIV · Entity 3185 | Exercise / conversionCommon Shares | 117,848 | $3.85 | $453,714.80 |
DisclosureSEC source: 0001140361-25-046786 · form4.xml · nonDerivative · entry 3 Venker Eric · CIK 0001801917 · President & Immunovant CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,729,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.